Tenaya Therapeutics Inc Asset Resilience Ratio
Tenaya Therapeutics Inc asset resilience ratio. Tenaya Therapeutics Inc (TNYA) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TNYA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tenaya Therapeutics Inc (2019–2024)
Asset resilience ratio of Tenaya Therapeutics Inc from 2019 to 2024. This chart shows how Tenaya Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of Tenaya Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tenaya Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TNYA asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Tenaya Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Tenaya Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Tenaya Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Tenaya Therapeutics Inc Asset Resilience Ratio by Year (2019–2024)
Tenaya Therapeutics Inc asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Tenaya Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.63% | $57.12 Million | $119.94 Million | +13.05pp |
| 2023-12-31 | 34.58% | $58.96 Million | $170.51 Million | +1.86pp |
| 2022-12-31 | 32.71% | $91.25 Million | $278.94 Million | -34.61pp |
| 2021-12-31 | 67.32% | $213.17 Million | $316.65 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $148.16 Million | -- |
| 2019-12-31 | 7.24% | $2.75 Million | $38.00 Million | -- |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more